Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
Phase 1
132
about 1.8 years
18–65
3 sites in CA, FL
What this study is about
Researchers are testing a treatment for psoriasis. The trial will evaluate how safe, tolerable, and effective this treatment is in healthy adults and people with moderate to severe plaque psoriasis.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.HS-20118 placebo
- 2.Take HS-20118
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation, Number of participants with clinical laboratory abnormalities
Secondary: AUC, Change from baseline in body surface area (BSA), Change from baseline in dermatology life quality index (DLQI), Change from baseline in psoriasis area and severity index (PASI) total score, Cmax, Tmax
Dermatology